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Summary
Background: Deleterious mutations in the BRCA1 and BRCA2 genes account for a considerable 
proportion of dominantly inherited breast and ovarian cancer susceptibility. The laboratory in-
terpretation has always been dependent on the information available at the time of the report 
conclusion. The aim of this study has been to review the results from the BRCA test ing at Masaryk 
Memorial Cancer Institute (MMCI). Patients and methods: Patients with suspected hereditary 
predisposition to breast/ ovarian cancer, belong ing to 7,400 families, were referred by genetic 
counsellors for BRCA1 and BRCA2 mutation test ing at the MMCI from 1999 to the beginn ing of 
2018. Various methods have been used over 20 years of laboratory practice – start ing with the 
Protein Truncation Test and Heteroduplex Analysis via the High Resolution Melt ing analysis and 
Sanger sequenc ing up to Next Generation Sequencing. Results: BRCA1 and BRCA2 mutation 
screen ing resulted in the identifi cation of 1,021 families with a germline high-risk BRCA1 muta-
tion and 497 families carry ing a high-risk BRCA2 mutation, represent ing a mutation detection 
rate of 20.5%. A broad spectrum of unique mutations classifi ed as pathogenic or likely patho-
genic has been detected in both genes – 124 in the BRCA1 and 123 in the BRCA2 gene. Other 
sequence variants (96 unique variants in the BRCA1 and 126 in the BRCA2 gene) have been 
revised and classifi ed as benign or likely benign. The other 82 unique variants remain classifi ed 
as of uncertain signifi cance mainly due to a lack of information for inclusion in other groups. 
All the results are summarised in the tables, includ ing the reasons for their classifi cation. Con-
clusion: The clinical classifi cation of rare sequence variants identifi ed in the high-risk breast 
cancer susceptibility genes BRCA1 and BRCA2 is essential for appropriate genetic counselling. 
Here we present an overview of BRCA mutation frequencies in our region and the retrospective 
evaluation and eventually reclassifi cation of previously reported rare variants in light of recent 
fi ndings.
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Introduction 
Several breast and ovarian cancer sus-
ceptibility genes have been identifi ed 
to date. The most important genes in 
the context of genetic counsell ing re-
main the BRCA1 and BRCA2. The germ-
line BRCA1/ 2  heterozygote frequency 
in individuals of European non-Finn-
ish descent  – BRCA1  mutation fre-
quency 0.21% (1  : 480) and BRCA2 mu-
tation frequency 0.31% (1  : 327); both 
combined 0.51% (1  : 195)  [1] was cal-
culated by examin ing publicly avail-
able data from the Exome Variant Server 
and the Exome Aggregation Consor-
tium database. However, these calcula-
tions do not incorporate large genomic 
rearrangements or uncharacterised, but 
potentially pathogenic, missense muta-
tions and, therefore, could be underesti-
mates of true population frequencies of 
BRCA1/ 2 heterozygotes [1]. These fi gures 
are in agreement with those obtained 
in an unselected population cohort of 
50,726 adults who underwent exome se-
quencing: 0.52% (n = 267) were found to 
be BRCA1/ 2 mutation carriers [2].
Mutations in the BRCA1 (MIM#113705) 
and BRCA2  (MIM#600185) account for 
an autosomal dominant transmission 
of susceptibility to breast and ovarian 
cancers. BRCA1/ 2  genes have been 
studied very well since their discovery 
in 1994 and 1995. The cumulative breast 
cancer risk up to the age of 80 was de-
termined at 72% for BRCA1 and 69% for 
BRCA2 mutation carriers [3]. Breast can-
cer incidences increased rapidly in early 
adulthood until the age of 30 to 40 for 
BRCA1 and until the age of 40 to 50 for 
BRCA2 mutation carriers, then remained 
relatively constant throughout the re-
mainder of the patient’s lifetime. The 
cumulative ovarian cancer risk up to 
the age of 80  was determined at 44% 
for BRCA1 and 17% for BRCA2 mutation 
carriers [3].
Genetic counsell ing has become an 
integral part of BRCA1/ 2  test ing and 
helps patients in mak ing informed deci-
sions about undergo ing testing. The re-
sults are used to plan optimal women’s 
treatment or clinical management op-
tions, which involve a  combination of 
early cancer screening, prophylactic sur-
gery and other risk reduction strategies. 
Genetic test ing may detect changes 
that are clearly pathogenic, clearly neu-
tral or variants of uncertain clinical sig-
nifi cance (VUS). Such variants present 
a  considerable challenge to the dia g-
nostic laboratory and the receiv ing clini-
cian in terms of interpretation. Adequate 
classifi cation of rare sequence changes 
identified in the high-risk breast can-
cer susceptibility genes BRCA1  and 
BRCA2  is essential for appropriate ge-
netic counsell ing of individuals carry ing 
these variants.
The aim of this study has been to re-
view the results from the BRCA test-
ing at Masaryk Memorial Cancer Insti-
tute (MMCI) dur ing the last 20 years of 
dia gnostic practice. This will give a nec-
essary overview of mutation frequen-
cies in our region and the retrospective 
evaluation and eventually reclassifi ca-
tion of previously reported rare variants 
in light of recent fi ndings. The report-
ing of novel sequence variants included 
a  clinical interpretation based on the 
best data available at the time of testing. 
Often, as subsequent studies were done, 
either within the same family in our re-
gion or others reported in literature, this 
clinical interpretation may need to be 
modifi ed or changed. When the causal 
status of a sequence variant is indeter-
minate, follow-up activities may be use-
ful to clarify this relationship and assist 
risk assessment.
A system of five classes of variants 
based on the degree of likelihood 
of pathogenicity is used as recom-
mended  [4] in agreement with the 
ACMG (American College of Medical Ge-
netics)  [5] / ENIGMA (Evidence-based 
Network for the Interpretation of Germ-
line Mutant Alleles) criteria [6]. Each class 
is associated with specifi c recommenda-
tions for clinical management of at-risk 
relatives.
Materials and methods
Patients, controls, 
and criteria for testing
The patients were referred to the MMCI 
in Brno for genetic counsell ing by phy-
Souhrn
Východiska: Patogenní mutace v genech BRCA1 a BRCA2 jsou majoritní příčinou dědičné dominantní predispozice ke vzniku nádoru prsu a vaječ-
níku. Interpretace molekulárně-genetických nálezů vždy závisí na dostupných informacích v době uzavření laboratorní zprávy. Cílem této studie 
byla revize klasifi kace všech výsledků testování BRCA genů v Masarykově onkologickém ústavu (MOÚ). Soubor pa cientů a metody: Pa cienti ze 
7 400 rodin s podezřením na dědičnou predispozici ke vzniku nádorů prsu a/ nebo vaječníků byli v MOÚ vyšetřeni v období let 1999 až první 
poloviny 2018. Vyšetření genů BRCA bylo vždy indikováno klinickým genetikem. V průběhu 20 let laboratorní praxe byly použity různé metody – 
počínaje vyšetřením cíleným na detekci zkrácené délky proteinu a heteroduplexní analýzu přes vysokorozlišovací analýzu křivek tání a Sange-
rovo sekvenování až po masivní paralelní sekvenování. Výsledky: Mutační analýza vedla k odhalení dědičné predispozice k nádoru prsu/ ovaria 
u 20,5 % rodin. Vysoce riziková zárodečná mutace byla detekována u 1 021 rodin v genu BRCA1 a u 497 rodin v genu BRCA2. Bylo zachyceno široké 
spektrum patogenních a pravděpodobně patogenních unikátních mutací v obou genech – 124 různých mutací v genu BRCA1 a 123 různých 
mutací v genu BRCA2. Jako benigní nebo pravděpodobně benigní bylo klasifi kováno 96 unikátních variant v genu BRCA1 a 126 variant v genu 
BRCA2. Zbývajících 82 vzácných unikátních variant zůstalo klasifi kováno jako „nejasného významu“, především z důvodu ojedinělého výskytu 
a nedostatku podkladů pro jejich zařazení do ostatních skupin. Výsledky jsou shrnuty v tabulkách dle typu mutace/ varianty vč. podkladů pro 
jejich klasifi kaci. Závěr: Co nejpřesnější klinická klasifi kace variant identifi kovaných v BRCA genech má dopad na genetické poradenství a násled-
nou klinickou péči. V této studii uvádíme přehled frekvencí BRCA mutací detekovaných v našem regionu, retrospektivní hodnocení a případně 
reklasifi kaci u ně kte rých dříve reportovaných variant ve světle nedávných zjištění.
Klíčová slova
nádor prsu – nádor ovaria – gen BRCA1 – gen BRCA2 – zárodečné mutace
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The fi rst experiences with the TruSight 
Cancer panel have been published else-
where [10]. Two hundred families were 
analysed with the TruSight cancer panel.
From 2016 onwards we have used the 
NimbleGen SeqCap EZ Choice (Roche) 
to create a  sequenc ing library with 
a  multi-gene panel called CZECANCA 
(CZEch CAncer paNel for Clinical Appli-
cation) accord ing to NimbleGen SeqCap 
EZ Library SR User’s Guide  [11]. Three 
hundred families were analysed with the 
CZECANCA cancer panel.
A FinalistDX integrated bio informatics 
comput ing system (Institute of Applied 
Biotechnologies) with a  Linux operat-
ing system (Ubuntu) was used for data 
process ing and analysis of MiSeq FASTQ 
fi les. FinalistDX software allows fast and 
comprehensive bio informatics analy-
sis from raw FASTQ fi les to quality con-
trol, alignment to the reference ge-
nome (bam, bai), coverage analysis, 
variants call ing (VCF fi les) and recently 
also copy number variations (CNV) 
analy sis with detailed reports in a  va-
riety of formats (tsv, xls, pdf ). The alter-
native bio informatics analysis, which 
was used in parallel, has been described 
elsewhere [11].
Nomenclature and variant 
classifi cation
All sequence variants have been named 
and are referred to in the text accord ing 
to the nomenclature used by the Human 
Genome Variation Society recommen-
dation guidelines  [12], us ing the A  of 
the ATG-translation initiation codon as 
nucleotide +1 [13]. Detected sequence 
alterations are described at the cod-
ing DNA reference sequence (cDNA) 
level accord ing to the BRCA1 most com-
mon human transcript (NM_007294.3) 
with the traditional number ing of exons 
1– 24 without the presence of exon 4, and 
accord ing to the BRCA2  (NM_000059.3) 
reference sequences.
The variants were assessed in Alamut® 
Visual software (Interactive Biosoftware) 
and other public databases (BIC, LOVD, 
UMD, ClinVar) to determine whether they 
were known in other populations. All 
variants were evaluated regard ing patho-
genicity follow ing the recommended 
terminology for classifi cation [4– 6]: 
(200– 540 bp) were amplifi ed. LCGreen® 
Plus was used as the intercalat ing dye 
for HRM analysis performed on a 96-well 
LightScanner™ (Idaho Technology Inc.). 
Later (start ing in 2012), the analysis of 
several highly polymorphic amplicons 
was transferred to dHPLC (Denatur ing 
High-Performance Liquid Chromatogra-
phy; Transgenomic Wave system 4500) 
for better resolution of polymorphic 
regions. Sanger sequenc ing was per-
formed on 3130 Genetic Analyser (Ap-
plied Biosystems) from 2007 with a Big-
Dye™ Terminator v3.1 Cycle Sequenc ing 
Kit (Applied Biosystems). 
In addition, we evaluated the fre-
quency of large genomic rearrange-
ments in the BRCA1 gene with Multiplex 
Ligation-dependent Probe Amplifica-
tion (MLPA) (MRC-Holland). More de-
tails about our pilot study have been 
reported elsewhere  [9]. MLPA for the 
BRCA1  gene (SALSA MLPA Probemix 
P002; and confi rmation Probemix P087; 
MRC Holland) has been the stand-
ard test since 2005. Focused on BRCA2, 
after test ing 1,000 high-risk individuals 
without the detection of any exon-
spann ing deletion/ duplication, MLPA 
for the BRCA2 gene has been removed 
from the standard protocol. MLPA for 
BRCA2  (SALSA MLPA Probemix P045; 
MRC Holland) was re-introduced as 
a standard test in 2015. Fragment analy-
sis was performed on a 3130 Genetic An-
alyser (Applied Biosystems); free MLPA 
analysis software, Coffalyser.net was 
used for data analysis (MRC-Holland) to-
gether with a  visual inspection of the 
fragment analysis profi le.
Next generation sequenc ing meth-
ods were introduced in our laboratory 
in 2014 and several hundred individuals 
from 500 unrelated families referred for 
hereditary breast and/ or ovarian cancer 
predisposition were tested up to mid-
2018. Next generation sequenc ing was 
performed on a MiSeq system (Illumina).
We started with a commercially avail-
able targeted enrichment TruSight Can-
cer panel (Illumina) includ ing 94  can-
cer predisposition genes along with the 
BRCA1/ 2 genes. All the procedures were 
performed accord ing to the manufac-
turers’ instructions – Trusight-rapid-cap-
ture-sample-prep protocol (Illumina). 
sicians from various specialisations or 
were sent for test ing by other medi-
cal geneticists from various parts of 
the Czech Republic between 1999  and 
2018. All the tested individuals provided 
a signed informed consent follow ing ap-
propriate genetic counselling. Genetic 
test ing was offered to high-risk indi-
viduals meet ing the recommended cri-
teria for BRCA testing. In this study, “fam-
ily” was defi ned by the practice of giv ing 
an index patient (proband) a  separate 
family number if he/ she did not already 
have family members registered in our 
laboratory. If another relative came, this 
person was included in the already reg-
istered family. The results of the test ing 
from 1999– 2018 include 7,400 high-risk 
families referred for genetic test ing in 
the context of a presumed genetic pre-
disposition for breast and/ or ovarian 
cancer. The criteria for genetic test-
ing have been revised and edited over 
20  years of genetic practice and have 
been published elsewhere in the frame-
work of the guidelines for the Czech
 Republic [7,8].
The control “cancer-free” group was 
composed of healthy individuals (150) 
above 60  years of age without the oc-
currence of cancer in their personal his-
tory and without the occurrence of tu-
mours of the breast, ovaries, prostate or 
colon cancer in their fi rst- or second-de-
gree relatives. All the control individuals 
provided a  signed informed consent 
with participation for the purposes of 
research.
Mutation screening
Genomic DNA was isolated from blood 
samples with a QIAamp DNA blood puri-
fi cation kit (Qiagen). Initially, individuals 
from approximately the fi rst 1,000 fami-
lies were analysed dur ing 1999– 2006 us-
ing the Protein Truncation Test and Het-
eroduplex Analysis followed by Sanger 
sequenc ing on the ALF  express™ DNA 
sequencer (Pharmacia) described 
elsewhere [8]. 
High-Resolution Melt ing (HRM) curve 
analysis was used to analyse individuals 
from 5,900  families dur ing 2007– 2017. 
To cover the complete cod ing region and 
splice sites of BRCA1 and BRCA2, 89 poly-
merase chain reaction (PCR) amplicons 
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 Tab. 1. BRCA1 nonsense and frame-shift mutations detected in Czech patients.
cDNA level 
(HGVS nomenclature)
Protein 
level
Number
of families
NFE frequency 
(gnom)
LOVD-IARC class [4] // our class 
(if diff erent or not specifi ed)
c.55C>T p.Gln19* 2 – class 5, pathogenic
c.68_69del p.Glu23Valfs*17 24 0.0087% class 5, pathogenic
c.143del p.Met48Serfs*2 1 – class 5, pathogenic
c.160C>T p.Gln54* 1 – class 5, pathogenic
c.303T>G p.Tyr101* 1 – class 5, pathogenic
c.485_486del p.Val162Glufs*19 1 – class 5, pathogenic
c.505C>T p.Gln169* 2 – class 5, pathogenic
c.622_625dup p.Pro209Hisfs*8 1 – // novel – // class 4: likely pathogenic; putative hypomorphic allele? 
c.676del p.Cys226Valfs*8 1 – class 5, pathogenic
c.737del p.Leu246* 1 – class 5, pathogenic
c.798_799del p.Ser267Lysfs*19 3 – class 5, pathogenic
c.843_846del p.Ser282Tyrfs*15 7 – class 5, pathogenic
c.890del p.Met297Argfs*3 1 – // novel –  // class 5, pathogenic
c.962G>A p.Trp321* 1 0.00090% class 5, pathogenic
c.963G>A p.Trp321* 1 – class 5, pathogenic
c.1016dup p.Val340Glyfs*6 7 – class 5, pathogenic
c.1016del p.Lys339Argfs*2 5 – class 5, pathogenic
c.1040del p.Leu347Argfs*27 1 – class 5, pathogenic
c.1068_1077del p.Gln356Hisfs*15 1 – class 5, pathogenic
c.1127del p.Asn376Ilefs*18 9 – class 5, pathogenic
c.1204del p.Glu402Serfs*8 4 – class 5, pathogenic
c.1273dup p.Ser425Phefs*11 5 – class 5, pathogenic
c.1403del p.Lys468Argfs*7 1 – class 5, pathogenic
c.1416del p.Asn473Thrfs*2 2 – class 5, pathogenic
c.1504_1508del p.Leu502Alafs*2 1 – class 5, pathogenic
c.1510del p.Arg504Valfs*28 7 – class 5, pathogenic
c.1600C>T p.Gln534* 5 – class 5, pathogenic
c.1687C>T p.Gln563* 36 0.0054% class 5, pathogenic
c.1938_1947del p.Ser646Argfs*2 1 – class 5, pathogenic
c.1953_1956del p.Lys653Serfs*47 1 – class 5, pathogenic
c.2022_2031dup p.Ala678Cysfs*8 1 – // novel –  // class 5, pathogenic
c.2024dup p.Thr676Asnfs*7 2 – // novel –  // class 5, pathogenic
c.2070_2071del2 p.Arg691Thrfs*2   1 – class 5, pathogenic
c.2157dup p.Glu720Argfs*6 2 – class 5, pathogenic
c.2193_2196del p.Glu732Argfs*3 1 – class 5, pathogenic
c.2233del p.Glu745Lysfs*8 1 – // novel –  // class 5, pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NFE – non-Finnish European, LOVD – Leiden 
Open Variation Database, IARC – International Agency for Research on Cancer
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 Tab. 1 – continuing. BRCA1 nonsense and frame-shift mutations detected in Czech patients.
cDNA level 
(HGVS nomenclature)
Protein 
level
Number
of families
NFE frequency 
(gnom)
LOVD-IARC class [4] // our class 
(if diff erent or not specifi ed)
c.2263G>T p.Glu755* 9 – class 5, pathogenic
c.2371_2372del p.Leu791Argfs*9 1 – // novel –  // class 5, pathogenic
c.2411_2412del p.Gln804Leufs*5 15 – class 5, pathogenic
c.2488_2497dup p.Leu833* 15 – class 5, pathogenic
c.2683C>T p.Gln895* 1 – class 5, pathogenic
c.2762del p.Gln921Argfs*79 10 – class 5, pathogenic
c.3018_3021del p.His1006Glnfs*17 1 – class 5, pathogenic
c.3164del p.Gly1055Alafs*4 1 – class 5, pathogenic
c.3239T>A p.Leu1080* 2 – class 5, pathogenic
c.3607C>T p.Arg1203* 1 0.0018% class 5, pathogenic
c.3621_3626delinsAA p.Leu1209Serfs*25 1 – class 5, pathogenic
c.3640G>T p.Glu1214* 2 – class 5, pathogenic
c.3642_3643del p.Asn1215Leufs*3 10 – class 5, pathogenic
c.3700_3704del p.Val1234Glnfs*8 114 – class 5, pathogenic
c.3756_3759del p.Ser1253Argfs*10 16 0.0027% class 5, pathogenic
c.3770_3771del p.Glu1257Glyfs*9 3 0.00090% class 5, pathogenic
c.3937C>T p.Gln1313* 1 – class 5, pathogenic
c.4035del p.Glu1346Lysfs*20 2 0.0087% class 5, pathogenic
c.4052T>A p.Leu1351* 5 – class 5, pathogenic
c.4062_4068del p.Asn1354Lysfs*10 1 – class 5, pathogenic
c.4065_4068del p.Asn1355Lysfs*10 2 0.00090% class 5, pathogenic
c.4161_4162del p.Gln1388GlufsX2 1 – class 5, pathogenic
c.4165_4166del p.Ser1389* 1 0.00090% class 5, pathogenic
c.4237G>T p.Glu1413* 1 – class 5, pathogenic
c.4243del p.Glu1415Lysfs*4 3 0.00090% class 5, pathogenic
c.4299_4302del p.Ile1433Metfs*22 1 – // novel –  // class 5, pathogenic
c.4339C>T p.Gln1447* 1 – class 5, pathogenic
c.4524G>A p.Trp1508* 1 – class 5, pathogenic
c.4530dup p.His1511Alafs*10 1 – // novel –  // class 5, pathogenic
c.4545del p.Ser1516Valfs*32 1 – // novel –  // class 5, pathogenic
c.4666C>T p.Gln1556* 1 – class 5, pathogenic
c.4689C>G p.Tyr1563* 6 0.0018% class 5, pathogenic
 c.4806del p.Gln1604Asnfs*2 1 – class 5, pathogenic
c.4878dup p.Ala1627Cysfs*52 2 – class 5, pathogenic
c.5030_5033del p.Thr1677Ilefs*2 2 – class 5, pathogenic
c.5177_5178del p.Arg1726Lysfs*5 2 – class 5, pathogenic
c.5251C>T p.Arg1751* 13 0.00079% class 5, pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NFE – non-Finnish European, LOVD – Leiden 
Open Variation Database, IARC – International Agency for Research on Cancer
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p.Lys3326* (rs11571833) has been 
found to be of clinically low signifi cance, 
associated with only very slightly inc-
reased risk of breast cancer (ORw 1.28; 
95% CI 1.17– 1.40, P = 5.9 × 10−6)  [26]. 
Therefore, other variants lead ing to 
a stop codon 3’ of codon 3326 are con-
sidered as class 2 variants. 
2)  Variants occurr ing in the consensus 
splice acceptor or donor sequence 
sites, either within 2  bp of exon-in-
tron junctions, when they are expe-
rimentally demonstrated to result in 
abnormal mRNA transcript and found 
to produce only transcript(s) carry ing 
a premature termination codon, or an 
in-frame deletion disrupt ing the ex-
pression of one or more known clini-
cally important residues.
3)  Missense variants that have been 
conclusively demonstrated, on the basis 
of data from linkage analysis of high-
-risk families, functional assays or bio-
chemical evidence, to have a deleterious 
eff ect on known functional domains. 
4)  Copy number deletion/ duplication 
variant that removes/ duplicates one 
or more exons spann ing a known cli-
nically important functional or is pro-
ven by laboratory studies to result in 
a  frameshift alteration predicted to 
dis rupt the expression of one or more 
known clinically important functional 
residues.
Results
BRCA1 fi ndings 
In total, there were 1,021  families con-
fi rmed to carry a high-risk BRCA1 muta-
Align-GVGD  [21], which combines the 
bio physical characteristics (side-chain 
composition, polarity and volume) of 
amino acids and protein multiple se-
quence alignments. We also applied 
PRIORS V2.0. The BRCA1 and BRCA2 Prior 
Probabilities database combines Prior 
Probabilities of pathogenicity from 
missense substitution severity and 
spiceogenity [22]. 
Alamut® Visual software (Interac-
tive Biosoftware) has been used since 
2015, which integrates several missense 
variant pathogenicity prediction tools 
and algorithms such as SIFT, PolyPhen2, 
Align-GVGD or MutationTaster; as well as 
the splic ing prediction tools mentioned 
above.
For in-frame deletions/ insertions we 
used PROVEAN (Protein Variation Eff ect 
Analyser) software [23], which predicts 
whether an amino acid substitution or 
indel will have an impact on the bio-
logical function of a protein [24].
More recently, the free interactive da-
tabase VarSome has been used as well, 
created by Saphetor SA for the human 
genomics annotation tool [25]. 
Defi nition of deleterious mutations 
Sequence variants were categorised on 
the basis of their predicted eff ect on the 
mRNA and amino acid level and defi ned 
as deleterious mutations accord ing to 
the ACMG/ ENIGMA criteria [5,6]: 
1)  Frameshift and nonsense variants in 
both genes, with the exception of 
BRCA2 variants lead ing to a stop codon 
3’of codon 3326 as BRCA2  c.9976A>T; 
• Class 5: pathogenic (probability of be-
ing pathogenic > 0.99);
• Class 4: likely pathogenic (probability 
of be ing pathogenic 0.95– 0.99);
• Class 3: uncertain signifi cance (proba-
bility of be ing pathogenic 0.05– 0.949);
• Class 2: likely benign (probability of 
be ing pathogenic 0.001– 0.049);
• Class 1: benign (probability of be ing 
pathogenic < 0.001).
Prediction of putative splice site 
variants and mRNA (cDNA) analysis
All putative splice site variants were 
tested us ing the Splice Site Prediction 
Programs for their potential to alter 
splicing. Several predictive programs 
were used as the NNSplice [14] or Net-
Gene2 [15]. Later, Alamut® Visual (Inter-
active Biosoftware) predictions on ribo-
nucleic acid (RNA) splicing, allow ing the 
assessment of their potential impact 
on splice junctions and visualization of 
cryptic or de novo splice sites, was used. 
Splic ing prediction tools included in Al-
amut are represented by NNSplice [14]; 
GeneSplicer  [16]; MaxEntScan  [17]; 
SpliceSiteFinder-like [18]. Subsequently, 
messenger RNA (mRNA) / cDNA analy-
sis was performed to verify ’in silico’ pre-
dictions in cases of previously not char-
acterised putative splice variants as 
described elsewhere [8,19,20].
In silico analyses for missense and in-
frame indel variants
Several prediction software were used 
includ ing Grantham Variation (GV) and 
Grantham Deviation (GD) scores, later 
 Tab. 1 – continuing. BRCA1 nonsense and frame-shift mutations detected in Czech patients.
cDNA level 
(HGVS nomenclature)
Protein 
level
Number
of families
NFE frequency 
(gnom)
LOVD-IARC class [4] // our class 
(if diff erent or not specifi ed)
c.5266dup p.Gln1756Profs*74 329 0.016% class 5, pathogenic
c.5346G>A p.Trp1782* 3 – class 5, pathogenic
c.5432del p.Gln1811Argfs*23 1 – // novel –  // class 5, pathogenic
c.5510G>A p.Trp1837* 2 – class 5, pathogenic
c.5511G>A p.Trp1837* 2 – class 5, pathogenic
c.5554del p.Thr1852Profs*3 1 – // novel –  // class 5, pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NFE – non-Finnish European, LOVD – Leiden 
Open Variation Database, IARC – International Agency for Research on Cancer
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Tab. 2. BRCA1 splice site alterations detected in Czech patients. 
cDNA level 
(HGVS 
nomenclature)
Number
of 
families
In silico Prediction:
Alamut average 
(MaxEnt/
NNSPLICE/SSF) 
[reference]: described mRNA analysis results // 
other important information 
LOVD-IARC class 
[4] // our class (if 
diff erent or not 
specifi ed)
c.213-12A>G 33
new acceptor 
site: c.213–11; WT 
acceptor: –35.0%
[29]: r.212_213ins213-12_213-1; p.(Arg71Serfs*21) class 5, pathogenic
c.213-11T>G 1 −96% [52]: r.212_213ins213-59_213-1UMD database: Intron inclusion: ins59Ter75
class 5, 
pathogenic
c.302-3C>G 1
new acceptor 
site: c.302−2; WT 
acceptor: −87,1% 
[8]: r.302-2_302-1insAG; p.(Tyr101*) class 5, pathogenic
c.4096+3A>T 1 −99.1%
[27]: enhanced Δ Ex 11; Δ 3309nt 3´of Ex 11: in-
-frame p.[(Ala224_Leu1365del);(Ser264_Leu1365del)] 
// [28]: healthy 58-years-old homozygous carrier of 
c.4096+3A>G
class 3, VUS
c.4185G>A 5 −68.9% [19]: r.4097_4185del; p.(Gly1366Alafs*8)[57 ]: r.4097_4185del 
class 5, 
pathogenic
c.4185+1G>C 1 −100%
novel; predicted exon skipping: r.(4097_4185del); se-
veral other pathogenic splice site alteration described 
all with exon skipping eff ect: c.4185+1G>T, c.4185+-
1G>A, c.4185+2T>C, c.4185G>A
class 4, likely 
pathogenic
c.4675+1G>A 1 −100%
[8]: several aberrant transcripts including minor wild-type 
and in-frame transcript: r.[=, 4358_4675del, 4485_4675del, 
4665_4675del, 4358_4484del, 4665_4675del] p. [=, 
Ala1453_Leu1558del, Ser1496Glyfs*14, Gln1556Glyfs*14, 
Ala1453Glyfs*10][57 ]: r.4485_4675del; [58]: Ex 15 deletion, 
11-bp deletion from Ex 15
class 4, likely 
pathogenic 
possible 
spliceogenic 
eff ect?
c.4674A>G; 
p.(Leu1558=) 1 −48.8% [20]: r.4665_4675del; p.(Gln1556Glyfs*14)
class 5, 
pathogenic
c.4676-1G>A 11 −100% // [59]: multifactorial likelihood ratio - pathogenic class 5, pathogenic
c.4868C>G, 
p.(Ala1623Gly) 1
new donor site; 
prior score: 0,64
[60 ]: r.4868_4986del p.(Ala1623Aspfs*16) // [61]: 
aff ects function
class 5, 
pathogenic
c.5074+3A>G 2 −61.5%
[62]: Ex 17 skipping and retention of 153 nt of intron 
17; LOVD database: Ex 17 skipping: r.4987_5074del => 
frame-shift 
class 5, 
pathogenic
c.5075-1G>A 2 −100%
LOVD database: in-frame Ex 18 ski-
pping r.5075_5152del => in-frame deletion 
p.(Asp1692_Trp1718delinsGly)
class 5, 
pathogenic
c.5152+1G>C 1 −100% [61]: aff ects function: r.5075_5152del => in-frame deletion 
class 5, 
pathogenic
c.5152+1G>T 1 −100% [61]: aff ects function: r.5075_5152del => in-frame deletion 
class 5, 
pathogenic
c.5152+2dupT 4 −93.2%
[20]: Ex 18 skipping r.5075_5152del => in-frame dele-
tion p.(Asp1692_Trp1718delinsGly)[61]: aff ects func-
tion: r.5075_5152del => in-frame deletion 
class 5, 
pathogenic
c.5468-1G>A 1
−100%, new 
acceptor splice 
site: c.5479
[20]: new acceptor site activated, deletion of 
fi rst 11nt of Ex: r.5468_5478del => frame-shift 
p.(Ala1823Aspfs*3)
class 5, 
pathogenic
c.5468-
-11_5520dup64 5
? tandem 
duplication
[61]: aff ects function: r.?; predicted frame-shift: 
p.(Ala1843Serfs*8)
class 4, likely 
pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, mRNA – messenger RNA, LOVD – Leiden Open Va-
riation Database, IARC – International Agency for Research on Cancer, WT – wild type, VUS – variants of uncertain clinical signifi cance
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Tab. 3. BRCA1 missense variants detected in Czech patients classifi ed as pathogenic (class-5) and likely pathogenic (class-4) 
cDNA level 
(HGVS 
nomen-
clature)
Protein
Number
of 
families
NFE freq. 
(gnom) Prior
Align-
-GVGD
[reference]: 
functional defect 
[reference]: 
other information
LOVD-
-IARC 
class [4] // 
our class 
(if diff e-
rent or not 
specifi ed)
c.53T>A p.Met18Lys 17 – 0,66 C55
[35]: disrupted he-
lical bundle; aff ects 
E2 (UbcH5b) bind-
ing // [36]: destabi-
lising BRCA1/BARD1 
complex
segregation with BC 
and OV cases in mul-
tiple families [37] in 
our recent study
class 4, 
likely 
pathogenic
c.71G>A p.Cys24Tyr 1 – 0,81 C65
[35]: loss of Zn2+ 
ligand residue of 
C3HC4 RING domain 
class 4, 
likely 
pathogenic
c.80G>A p.Cys27Tyr 1 – // novel 0,81 C65
[35]: loss of Zn2+ 
ligand residue of 
C3HC4 RING domain 
splice prediction: 
–10,8%; 
class 4, 
likely 
pathogenic
c.115T>C p.Cys39Arg 21 – 0,81 C65
[35]: loss of Zn2+ 
ligand residue of 
C3HC4 RING domain 
[63]: deleterious; 
[34]: pathogenic; 
[64]: pathogenic 
mutation
class 5: 
pathogenic
c.181T>G p.Cys61Gly 69 0.0063% 0,81 C65
[35]: loss of Zn2+ 
ligand residue of 
C3HC4 RING domain 
[63]: deleterious; 
[34]: pathogenic
class 5: 
pathogenic
c.191G>A p.Cys64Tyr 2 – 0,81 C65
[35]: loss of Zn2+ 
ligand residue of 
C3HC4 RING domain 
[61]: aff ects func-
tion; [64]: pathogenic 
mutation
class 5: 
pathogenic
c.5054C>A p.Thr1685Asn 1 – // novel 0,66 C55 BRCT domain
[34]: other variants: 
Thr1685Ile and Th-
r1685Ala – reported 
pathogenic
– // class 
4, likely 
pathogenic
c.5089T>C p.Cys1697Arg 1 – 0,81 C65
BRCT domain; [65]: 
folding defect, com-
promised transcrip-
tion assay, but un-
certain binding 
specifi city
[66]: loss of transacti-
vation activity in 
yeast and mamma-
lian cells
– // class 
4, likely 
pathogenic
c.5095C>T p.Arg1699Trp 1 0.0018% 0,81 C65
BRCT domain; [65]: 
strong functional 
eff ect
[34]: pathogenic; 
[64]: pathogenic 
mutation
class 5: 
pathogenic
c.5096G>A p.Arg1699Gln 1 0.0054% 0,66 C35
BRCT domain; [65]: 
strong functional 
eff ect
[67]: mRNA: no 
change [34]: patho-
genic; [39]: hypomor-
phic risk: OR 4,3 (95% 
CI 1.43–12.85)
hypomor-
phic risk: 
OR 4,3
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, GVGD – Grantham Variation and Grantham De-
viation, NFE – non-Finnish European, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Cancer, 
BRCT – BRCA1 C-terminal, OR – odds ratio, VUS – variants of uncertain clinical signifi cance
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most common missense mutations were 
in the RING domain aff ect ing the Zn2+ li-
gand residues of C3HC4 fi nger domain – 
p.Cys61Gly (detected in 69 families) and 
p.Cys39Arg (detected in 21 families). 
An overview of all large intra-
genic rearrangements detected in the 
BRCA1  gene have been provided in 
Tab. 4. There were 102 families with large 
intragenic rearrangements, represent-
ing 16 diff erent unique mutations clas-
sified as pathogenic (class 5) or likely 
pathogenic (class 4). The most common 
large intragenic rearrangements were 
deletions spann ing exons 5_14  (c.135-
485_4485-913del), detected in 36 fami-
lies and spann ing exons 21_22 (c.5278-
492_5406+1290delins236), detected in 
21 families.
A summary of BRCA1  in-frame de-
letions/ insertions detected in Czech 
high-risk families is provided in the sup-
plementary Tab. 5. All of them are con-
sidered as VUS (class 3).
The remain ing BRCA1 missense alter-
ations classifi ed as VUS (class 3), likely 
benign (class 2) and benign (class 1) 
summarised in Tab.  2. They concern 
71  families, represent ing 16  different 
deleterious splice site mutations clas-
sified as pathogenic (class 5) or likely 
pathogenic (class 4). One splice site al-
teration c.4096+3A>T lead ing to 2  in-
frame transcripts at the cDNA level (exon 
11 skipp ing and Δ3309nt 3’end of exon 
11) and previously classifi ed as patho-
genic by [27] was reclassifi ed as a variant 
of VUS, based on segregation data and 
the fi nd ing of a healthy 58-year-old ho-
mozygous woman for c.4096+3A>G 
variant in a consanguineous Danish fam-
ily with several cases of breast/ ovarian 
cancer [28]. However, in the Danish pop-
ulation BRCA1 c.4096+3A>G is now con-
sidered as likely benign  [28]. The most 
common splice site mutation was c.213-
12A>G (detected in 33 families), activat-
ing a  cryptic splice site and caus ing 
a frameshift [29]. 
All BRCA1 pathogenic missense muta-
tions are shown in Tab. 3. In 118 families, 
13 diff erent unique missense alterations, 
classifi ed as pathogenic (class 5) or likely 
pathogenic (class 4) were detected. The 
tion (13.8% of the 7,400 families analysed). 
The majority of clinically deleterious mu-
tations detected in the BRCA1 gene were 
protein-truncat ing mutations (731 fami-
lies with frameshift or nonsense muta-
tions), followed by missense mutations 
located in the RING domain and less fre-
quently by BRCT (BRCA1 C-terminal) do-
mains (118  families), large intragenic 
rearrangements (102 families) and splice 
site mutations (70 families). 
An overview of the BRCA1  frameshift 
and nonsense mutations detected in 
Czech high-risk families is provided in 
Tab.  1. We identifi ed 731  families with 
frameshift or nonsense mutations in 
the BRCA1  gene, which accounted for 
79  different unique deleterious mu-
tations. The most common mutations 
are c.5266dup (p.Gln1756Profs*74) de-
tected in 329  families; c.3700_3704del 
(p.Val1234Glnfs*8), detected in 114 fam-
ilies; c.1687C>T (p.Gln563*), detected in 
36 families; c.68_69del (p.Glu23Valfs*17), 
detected in 24 families.
The BRCA1  splice site mutations de-
tected in high-risk Czech families are 
Tab. 3 – continuing. BRCA1 missense variants detected in Czech patients classifi ed as pathogenic (class-5) and likely pathoge-
nic (class-4) 
cDNA level 
(HGVS 
nomen-
clature)
Protein Number
of 
families
NFE freq. 
(gnom)
Prior Align-
-GVGD
[reference]: 
functional defect 
[reference]: 
other information
LOVD-
-IARC 
class [4] // 
our class 
(if diff e-
rent or not 
specifi ed)
c.5123C>A p.Ala1708Val 1 0.0027% 0,81 C65
BRCT domain; [65]: 
strong functional 
eff ect
[30]: partial 
exon skipping: 
r.5075_5152del; 
class 3: 
VUS // class 
4: likely 
pathogenic
c.5145C>G p.Ser1715Arg 1 – 0,81 C65 BRCT domain; [65]: 
strong functional 
eff ect; [66]: loss of 
transactivation acti-
vity in yeast and ma-
mmalian cells;
[34]: pathogenic; 
[64]: pathogenic 
mutation
class 5: 
pathogenic 
c.5360G>A p.Cys1787Tyr 1 – // novel 0,81 C65 BRCT domain [68]: p.Cys1787Ser 
is classifi ed as 
pathogenic
– // class 
4, likely 
pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, GVGD – Grantham Variation and Grantham 
Deviation, NFE – non-Finnish European, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Can-
cer, BRCT – BRCA1 C-terminal, OR – odds ratio, VUS – variants of uncertain clinical signifi cance
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Tab. 4. BRCA1 large intragenic rearrangements detected in Czech patients.
BRCA1 
(NM_007294.3)
exons aff ected
HGVS nomenclature
Number 
of 
families
[reference]: breakpoints; 
predicted change
LOVD-IARC class 
[4]) // our class (if 
diff erent or not 
specifi ed)
deletion of pro-
motor 1a_2 c.(?_-232)_(80+1_81-1)del 8
deletion detectable by primers published by 
[69]: deletion of 36.9 kb; class 5, pathogenic
deletion 
of exons 1a_17
c.(?_-232)_(5074+1_5075-1)
del 10 breakpoints not characterized
class 4, likely 
pathogenic
deletion 
of exons 5_ 14
c.135-485_4485-913del
Chr17(GRCh38):g.43075434_
43107018del
36 [9]: breakpoints characterised on RefSeq L78833.1: g.21716_53298del class 5, pathogenic
deletion of 
exon 8
c.(441+1_442-1)_
(547+1_548-1)del 7
breakpoints not characterized; deletion size 
about 4 kb (LR-PCR); predicted: r.(442_547del) 
=> frame-shift 
class 5, pathogenic
deletion from 
exon 11_12
c.1644_4185+3618del 
Chr17(GRCh38):g.43087326_
43093887del
2 [9]: breakpoints characterised on RefSeq L78833.1: g.34845_41405del; predicted: r.?
class 4, likely 
pathogenic
duplication of 
exon 13
c.(4185+1_4186-1)_
(4357+1_4385-1)dup 2
breakpoints not characterized; predicted (if 
tandem): r.(4186_4357)dup => frame-shift
class 4, likely 
pathogenic
duplication of 
exons 13_14
c.(4185+1_4186-1)_
(4484+1_4485-1)dup 2
breakpoints not characterized; predicted (if 
tandem): r.(4186_4484)dup => frame-shift 
class 4, likely 
pathogenic
deletion of 
exons 13_15
c.(4185+1_4186-1)_
(4675+1_4676-1)del 1
breakpoints not characterized; predicted: 
r.(4186_4675)del => frame-shift class 5, pathogenic
deletion 
of exon 17
c.(4986-1_4987+1)_
(5074+1_5075-1)del 1
breakpoints not characterized; deletion size 
about 2,4 kb (LR-PCR) predicted: r.(4987_5074)
del => frame-shift
class 5, pathogenic
deletion of 
exons 18_19
c.5075-1131_5193+190del 
Chr17(GRCh38):g.43063143_
43065082del
1
[9]: breakpoints characterised on GeneBank 
RefSeq L78833.1: g.63651_65590del; predicted: 
r.(5075_5193)del => frame-shift
class 5, pathogenic
deletion 
of exons 18_22
c.(5074-1_5075+1)_
(5406+1_5407-1)del 3
breakpoints not characterized; predicted: 
r.(5075_5406)del => frame-shift class 5, pathogenic
deletion 
of exon 20
c.5193+340_5277+2206
delChr17(GRCh38):-
g.43054846_43062993del
1
breakpoints characterised on GeneBank Ref-
Seq L78833.1 (our study): g.65740_73887del; 
predicted: r.(5194_5277)del => in-frame dele-
tion p.(His1732_Lys1759del)
class 5, pathogenic
deletion
of exon 20
c.5194-2834_5277+4111del
Chr17(GRCh38):g.43052941_
43059969del
1
[9]: breakpoints characterised on Gene-
Bank RefSeq L78833.1: g.68764_75792del; 
predicted: r.(5194_5277del) => in-frame: 
p.(His1732_Lys1759del)
class 5, pathogenic
deletion 
of exons 21_22
c.5278-492_5406+1290
delins236
Chr17(GRCh38):g.43047831_
43051609delins236
21
[9]: breakpoints characterised on GeneBank 
RefSeq L78833.1: g.77128_80906delins236; 
predicted: r.(5278_5406)del => in-frame 
p.(Ile1760_Thr1802del) 
class 5, pathogenic
duplication of 
exon.23
c.(5406+1_5407-1)_
(5467+1_5468-1)dup 1
breakpoints not characterized; predicted (if 
tandem): r.(5407_5467)dup => frame-shift
class 4, likely 
pathogenic
deletion of the 
entire BRCA1 
gene (exons 
1a_24)
c.(?_-232)_(*1_?)del 5 breakpoints not characterized; the whole allele deleted class 5, pathogenic
HGVS – Human Genome Variation Society, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on 
Cancer, LR-PCR – long-range polymerase chain reaction
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Tab. 8. BRCA2 nonsense and frame-shift mutations detected in Czech patients. 
cDNA level (HGVS 
nomenclature)
Protein 
level
Number
of families
NFE frequency 
(gnom)
LOVD-IARC class [4] // our class 
(if diff erent or not specifi ed)
c.-7_7del p.? 1 – // novel – // class 5, pathogenic
c.306dup p.Leu103Ilefs*10 1 – – // class 5, pathogenic
c.462_463del p.Asp156* 4 – class 5, pathogenic
c.593T>G p.Leu198* 1 – // novel – // class 5, pathogenic
c.635_636del p.Arg212Lysfs*2 3 – class 5, pathogenic
c.658_659del p.Val220Ilefs*4 14 0.0048% class 5, pathogenic
c.691_704del p.Tyr232* 1 – // novel – // class 5, pathogenic
c.755_758del p.Asp252Valfs*24 1 0.0018% class 5, pathogenic
c.1023_1024del p.Cys341* 1 – // novel – // class 5, pathogenic
c.1296_1297del p.Asn433Glnfs*18 2 – class 5, pathogenic
c.1310_1313del p.Lys437Ilefs*22 1 – class 5, pathogenic
c.1389_1390del p.Val464Glyfs*3 6 – class 5, pathogenic
c.1408dup p.Glu470Glyfs*6 1 – class 5, pathogenic
c.1414C>T p.Gln472* 1 – class 5, pathogenic
c.1560_1561del p.Ser521Argfs*5 1 – class 5, pathogenic
c.1796_1800del p.Phe599* 3 0.00090% class 5, pathogenic
c.1813dup p.Ile605Asnfs*11 5 0.0019% class 5, pathogenic
c.1989del p.Phe663Leufs*5 3 – class 5, pathogenic
c.2251dup p.Thr751Asnfs*2 2 – class 5, pathogenic
c.2808_2811del p.Ala938Profs*21 26 0.0027% class 5, pathogenic
c.2828_2831del p.Ile943Lysfs*16 1 – class 5, pathogenic
c.2905C>T p.Gln969* 1 – class 5, pathogenic
 c.3075_3076delinsTT p.Lys1025_Lys1026de-linsAsn* 6 – class 5, pathogenic
c.3085del p.Met1029Cysfs*14 2 – // novel – // class 5, pathogenic
c.3195_3198del p.Asn1066Leufs*10 4 – class 5, pathogenic
c.3545_3546del p.Phe1182* 1 0.0045% class 5, pathogenic
c.3641dup p.Phe1216Valfs*2 1 – class 5, pathogenic
c.3703C>T p.Gln1235* 1 – // novel – // class 5, pathogenic
c.3744_3747del p.Ser1248Argfs*10 3 – class 5, pathogenic
c.3847_3848del p.Val1283Lysfs*2 16 0.0082% class 5, pathogenic
c.3860del p.Asn1287Ilefs*6 1 0.0022% class 5, pathogenic
c.3967A>T p.Lys1323* 1 – class 5, pathogenic
c.3975_3978dup p.Ala1327Cysfs*4 4 0.00100% class 5, pathogenic
c.4284dup p.Gln1429Serfs*9 3 0.0067% class 5, pathogenic
c.4440T>G p.Tyr1480* 7 – class 5, pathogenic
c.4544delA p.Lys1515Argfs*28 4 – class 5, pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NC – not counted, NFE – non-Finnish Euro-
pean,  LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Cancer, mRNA – messenger RNA
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analysis and therefore, their frequency 
would be underestimated.
Discussion
Deleterious mutations in the BRCA1 and 
BRCA2  genes account for a  consider-
able proportion of dominantly inherited 
breast and ovarian cancer susceptibil-
ity and have received wide acceptance 
in dia gnostic test ing and prevention. 
The classifi cation of sequence variants 
into high-risk or low-risk categories is 
both challeng ing and critical for clar-
ification of the causative status. Only 
class 5  (pathogenic) and class 4  (likely 
pathogenic) can be used for guidance 
of clinical management. However, this 
classification system does not allow 
distinguish ing between highly pene-
trant and hypomorphic alleles (like 
BRCA1 c.5096G>A; p.Arg1699Gln) [31].
BRCA1 and BRCA2 mutation screen ing 
in our laboratory resulted in the identifi -
cation of 1021 families with deleterious 
BRCA1 mutations and 497  families with 
a BRCA2 mutation, result ing in a mutation 
detection ratio of 20.5%. A broad spec-
trum of diff erent deleterious mutations 
was found in both genes  – 124  unique 
mutations in BRCA1  and 123  unique 
mutations in BRCA2. The most frequent 
were small frameshift and nonsense mu-
tations  – 174  unique mutations (79  in 
BRCA1 and 95  in BRCA2) scattered in all 
regions of the cod ing sequences. 
A missense mutation that leads to 
a  non-conservative substitution of an 
evolutionarily conserved amino acid is 
more likely to be causative than a mis-
sense mutation that leads to a conserva-
tive substitution or alters an amino acid 
that is not evolutionarily conserved [5]. 
The PRIORS probability tool seems to 
have the strongest predictive value in 
agreement with already known delete-
rious missense mutations. The extent to 
which a  sequence variation is consid-
ered causative of dis ease may be infl u-
enced by multiple parameters such as 
family history, segregation of the variant 
with aff ected relatives in a family, nature, 
and position of the amino acid substitu-
tion, evolutionary conservation of the af-
fected residue, co-occurrence with a del-
eterious mutation, epidemiological and 
case/ control studies, functional in vitro 
tion was c.475G>A, a substitution aff ect-
ing the last nucleotide of exon 5  for 
which RNA analysis has demonstrated 
that it causes abnormal splic ing and re-
sults in a frameshift and a truncated pro-
tein [8], was detected in 10 families.
The deleterious BRCA2 missense mu-
tations detected in high-risk Czech fam-
ilies can be found in Tab. 10. There were 
44  families carry ing a  deleterious mis-
sense mutation, represent ing 15 diff er-
ent mutations classifi ed as pathogenic 
(class 5) or likely pathogenic (class 4). 
With the exception of one mutation in 
the initiation codon, all deleterious mis-
sense mutations were located in the DBD 
domain. The most common missense 
mutation, classifi ed as likely patho genic 
was c.9371A>T (p.Asn3124Ile), detected 
in 16 families. 
Of the total study cohort, only about 
3,000  families were analysed for large 
intragenic rearrangements by MLPA (or 
later CNV analysis). Only 4 families were 
found to carry a  large intragenic rear-
rangement in BRCA2  (Tab.  11). In one 
of the complex BRCA2  rearrangements 
we have not been able to reveal the 
exact character of the complex changes 
(Fig. 1). Because of the low frequency of 
BRCA2  large intragenic rearrangements, 
we did not perform a  retrospective 
analy sis of all previously unsolved cases.
The remain ing BRCA2 missense alter-
ations, classifi ed as VUS (class 3), likely 
benign (class 2) and benign (class 1) 
are summarised in the supplementary 
Tab. 12, includ ing the reasons for their 
classifi cation. Silent variants were not in-
cluded if, on the basis of the prediction 
the chance of aff ect ing splic ing was very 
low. A  summary of the BRCA2  intronic 
variants is provided in the supplemen-
tary Tab. 13.
Dur ing these 20 years the majority of 
variants, which were originally reported 
as of VUS, could be reclassifi ed as likely 
benign or benign. As soon as informa-
tion confirm ing the neutrality of any 
missense or intronic variant was avail-
able, we ceased to register their fre-
quency and to report them. The fre-
quency of neutral variants was not 
monitored because homozygotes of fre-
quent variants were not detectable by 
screen ing with Heteroduplex nor HRM 
are summarised in the supplementary 
Tab.  6, includ ing the reasons for their 
classification. Silent variants were not 
included if, on the basis of the predic-
tion the chance of aff ect ing splic ing was 
very low. A summary of BRCA1  intronic 
variants targeted mainly up to position 
+/ −50 to exon is provided in the supple-
mentary Tab. 7.
BRCA2 fi ndings 
In total, there were 497  families con-
fi rmed to carry high-risk BRCA2  muta-
tion (6.7% of the 7,400 families analysed). 
Most clinically deleterious mutations de-
tected in the BRCA2 gene were protein-
truncat ing mutations (404  families 
with deleterious frameshift or non-
sense mutation), followed by splice site 
mutations (45  families), missense mu-
tations with the exception of the mu-
tation in the initiation codon located in 
the DBD (DNA/ DSS1  binding) domain 
(44  families) and large intragenic rear-
rangements turned out to be very rare 
(4 families).
A summary of the frameshift and 
nonsense mutations detected in Czech 
high-risk families in BRCA2  is pro-
vided in Tab.  8. In total, 404  families 
were identifi ed with a  truncat ing mu-
tation, represent ing 95  diff erent dele-
terious mutations. The most com-
mon mutations were: c.8537_8538del 
(p.Glu2846Glyfs*22), detected in 61 fam-
ilies; c.7913_7917del (p.Phe2638*), de-
tected in 37  families; c.2808_2811del 
(p.Ala938Profs*21), detected in 26 fami-
lies. Two variants lead ing to a stop codon 
3’ of codon 3326  were very frequent  – 
p.Lys3326* and c.10095delC insGAATTA-
TATCT (p.Ser3366Asnfs*4).
An overview of the BRCA2  splice site 
mutations detected in high-risk Czech 
families is shown in Tab.  9. There were 
46  families carry ing a  splice site alter-
ation, represent ing 9  diff erent delete-
rious splice site mutations classified 
as pathogenic (class 5) or likely patho-
genic (class 4). One splice site altera-
tion, c.9501+3A>T, previously described 
as pathogenic and caus ing partial exon 
skipp ing (the aberrant transcript repre-
sented only 13% of the wild type tran-
script [30]) was reclassifi ed as a variant of 
VUS. The most common splice site muta-
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high-risk deleterious mutations [32], (LOVD 
database). In the BRCA2 gene only some 
missense variants located in the most con-
served C-terminal DNA bind ing DBD do-
main (amino acids 2460– 3170) have been 
confi rmed to be high-risk deleterious mu-
tations [33,34], (LOVD database).
For BRCA1  only missense variants lo-
cated in the highly conserved RING fi nger 
domain at the N-terminal region (amino 
acids 1– 109) and in the transcriptional ac-
tivation domain with two BRCT repeats 
(amino acids 1640– 1729 and 1760– 1821) 
at the C-terminal region are considered 
studies or knock-out animal models [5]. 
A novel variant of VUS with neutral pre-
dictions in less conserved regions that 
are unlikely to aff ect splic ing were al-
ways mentioned in the report but inter-
preted as a  variant suspected to be of 
low clinical signifi cance. 
Tab. 8 – continuing. BRCA2 nonsense and frame-shift mutations detected in Czech patients. 
cDNA level (HGVS 
nomenclature)
Protein 
level
Number
of families
NFE frequency 
(gnom)
LOVD-IARC class [4] // our class 
(if diff erent or not specifi ed)
c.7069_7070del p.Leu2357Valfs*2 1 0.0055% class 5, pathogenic
c.7151_7152del p.Gln2384Argfs*7 1 – class 5, pathogenic
c.7471C>T p.Gln2491* 3 – class 5, pathogenic
c.7649del p.Ile2550Lysfs*98 1 – // novel – // class 5, pathogenic
c.7718T>A p.Leu2573* 1 – // novel – // class 5, pathogenic
c.7887G>A p.Trp2629* 1 – class 5, pathogenic
c.7913_7917del p.Phe2638* 37 – class 5, pathogenic
c.8042_8043del p.Thr2681Serfs*11 8 – class 5, pathogenic
c.8172_8175dup p.Tyr2726Valfs*5 4 – class 5, pathogenic
c.8322dup p.Met2775Tyrfs*7 1 – class 5, pathogenic
c.8343del p.Asn2781Lysfs*40 1 – class 5, pathogenic
c.8363G>A p.Trp2788* 13 – class 5, pathogenic
c.8537_8538del p.Glu2846Glyfs*22 61 0.0027% class 5, pathogenic
c.9053_9057del p.Ser3018Ilefs*2 2 – class 5, pathogenic
c.9097dup p.Thr3033Asnfs*11 8 0.0028% class 5, pathogenic
c.9145dup p.Tyr3049Leufs*23 1 – // novel – // class 5, pathogenic
c.9147C>A p.Tyr3049* 1 – class 5, pathogenic
c.9366_9367del p.Ser3123Glnfs*26 1 – class 5, pathogenic
c.9382C>T p.Arg3128* 4 0.00079% class 5, pathogenic
c.9403del p.Leu3135Phefs*28 13 – class 5, pathogenic
c.9435_9436del p.Ser3147Cysfs*2 6 0.00090% class 5, pathogenic
c.9463_9467delinsGAA-
TGATC p.Phe3155Glufs*2 2 class 5, pathogenic
c.9976A>T p.Lys3326* NC (> 40) 0.86%
class 1, benign; [76]: functional 
assays: no eff ect; [34]: 
benign; [26]: BC risk OR 1.28, (95% 
CI 1.17–1.40), OC risk OR 1.26 
(95% CI 1.10–1.43); § (our study): 
detected in cancer free controls: 
c.10095delC 
insGAATTATATCT p.Ser3366Asnfs*4 NC (> 30) –
class 2, likely benign; Ω [67]: 
mRNA analysis: no change; § (our 
study): detected in cancer free 
controls
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NC – not counted, NFE – non-Finnish Euro-
pean,  LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Cancer, mRNA – messenger RNA
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databases). More frequently p.Met18Thr 
has been reported, which is also classifi ed 
as likely pathogenic [38] even with milder 
Align-GVGD predictions (C45  vs. C55  for 
p.Met18Lys). 
Several previously classified delete-
rious missense mutations have been 
heterodimerisation of BRCA1/ BARD1 com-
plex, was considered as a  likely patho-
genic variant  [35– 37]. BRCA1 p.Met18Lys 
is a Czech founder mutation detected in 
17 unrelated Czech families, with multiple 
breast and/ or ovarian cancer patients, but 
is rare in other populations (ClinVar, LOVD 
Besides the five deleterious missense 
mutations at the strongly conserved 
C3HC4 Zn
2+ ligand cysteine residues of the 
RING domain (Cys24, Cys27, Cys39, Cys61, 
Cys64), only p.Met18Lys, disrupt ing the hel-
ical bundle of the RING domain, aff ect ing 
E2 (UbcH5b) bind ing and destabilis ing the 
Tab. 9. BRCA2 splice site alterations detected in Czech patients.
cDNA level 
(HGVS 
nomenclature)
Number
of families
In silico Prediction: 
Alamut average 
(MaxEnt/NNSPLICE/
SSF) 
[reference]: described mRNA analysis // 
other important information 
LOVD-IARC class [4] // 
our class (if diff erent 
or not specifi ed)
c.475G>A 10 −50.6% [8]: r.426_475del p.(Phe143Glyfs*23) class 5, pathogenic
c.475+1G>T 3 −100% (our study): r.426_475del p.(Phe-
143Glyfs*23); [52]: Ex 5 skipping 
r.426_475del 
class 5, pathogenic
c.476-2A>G 6 −100% [8]: two transcripts r.[426_516del, 
476_516del] p.[Phe143Valfs*12; Val-
159Glyfs*10]; [52] Colombo 2013: 
r.[=,476_516del,426_516del] 
class 5, pathogenic // 
possible spliceogenic 
eff ect?
c.7007G>Ap.
(Arg2336His)
9 −53.8% [8]: three transcripts r.[6842_6937del, 
6842_7007del, 6938_7007del] 
p.[Glu2281_Gly2313del, Gly2280Alafs*31, 
Gly2313Alafs*31]; [30]: Ex13 skipping: 
r.6938_7007del; [77]: ES cell-based assay: 
deleterious
class 5, pathogenic // 
possible spliceogenic 
eff ect? 
c.7805+1G>C 1 −100% Novel; recently described only c.7805+-
1G>A and c.7805+1G>T – both as patho-
genic: r.spl (mRNA not characterised; LOVD 
database)
– // class 4, likely 
pathogenic
c.8486A>G 
p.(Gln2829Arg)
3 −11.8% [78]: r.8332_8487del p.(Ile2778_Gln-
2829del); [61]: in-frame deletion of Ex19; 
(our study): Ex 19 skipping in the main 
eff ect, but several alternative transcripts 
were observed also in control persons (skip 
of Ex 17,18, 20)
– // class 4, likely 
pathogenic; possible 
spliceogenic eff ect?
c.8755-1G>A 6 −100% [8]: r.8755_8953del p.(Gly2919fs*3); 
[52] r.[=,8755_8953del, 8755_9004del] 
p. [Gly2919Leufs*3,Gly2919Lysfs*26]; 
[30]: cryptic splice (83%) and Ex 22 ski-
pping (17%): r.[8755del,8755__8953del] 
p.[Gly1919Valfs*8,Gly2919Leufs*3] 
class 5, pathogenic
c.9117+2T>A 4 −100% [8]: r.8954_9117del p.(Val2985Glyfs*4) class 5, pathogenic
c.9118-2A>G 3 −100%, strong cryptic 
acceptor 
[19]: cryptic splice r.9118_9124del 
p.(Val3040Metfs*20) 
class 5, pathogenic
c.9501+3A>T 1 −58% [73]: incomplete Ex 25 skipping r.[=,9257_
9501del] p.[=,Gly3086Glufs*3]
[58]: Ex 25 skipping: r.9257_9501del
[49]: Partial Ex 25 skipping (13%): 
r.[=,9257_9501del]
confl icting: class 5, 
class 3 // class 3, VUS; 
strong spliceogenic 
eff ect, hypomorphic?
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, mRNA – messenger RNA, LOVD – Leiden Open 
Variation Database, IARC – International Agency for Research on Cancer, VUS – variants of uncertain clinical signifi cance
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the high-risk mutation (class 5, defi ni-
tively pathogenic) was detected. In two 
families with double-sided risk of breast 
and ovarian cancers a  case was found 
with double BRCA1 and BRCA2 risk mu-
tation – (family-340: BRCA1 p.Met18Lys 
together with BRCA2 p.Arg3052Trp – in 
a woman dia gnosed with breast cancer 
at the age of 41 and with Fallopian tube 
cancer at age of 52) and (family-5597: 
BRCA1 p.Met18Lys together with splice 
BRCA2  c.7007G>A  – in woman dia g-
nosed with triple negative breast cancer 
at the age of 40). 
The case report about one of our fam-
ilies with a  double-sided risk of breast 
cancer and three aff ected children dia g -
nosed with Fanconi anaemia carry-
ing bi-allelic FANCD1/ BRCA2  muta-
tions: c.[(658_659del);(9366_9367del)] 
has been described elsewhere [44]. The 
breast cancer genes, BRCA1 and BRCA2, 
are both essential for viability, there-
fore at least one of these bi-allelic muta-
tions in BRCA2  in patients with Fanconi 
anaemia-D1 subtype should have a hy-
pomorphic nature. BRCA2 c.658_659del 
is described repeatedly in association 
with eight cases of Fanconi anaemia-
D1  patients (LOVD database: Variants 
associated with Fanconi anaemia) 
whereas c.9366_9367del is submitted 
only once there for association with FA 
(our case;  [44]). Therefore, the strong-
est candidate for BRCA2  hypomorphic 
mutation is BRCA2  c.658_659del (pre-
viously 886delGT by BIC nomenclature) 
in exon 8 described in association with 
Fanconi anaemia and medulloblastoma 
in several cases  [44– 46]. Several natu-
rally occurr ing alternative transcripts in 
BRCA2 were described [47] which might 
bypass the lethality of deleterious mu-
tation by residual alternative splic ing 
in some regions [48], however no natu-
ral alternative transcript interfer ing with 
exon 8 of BRCA2 was described. 
The fi rst hypomorphic missense mu-
tations with reduced penetrance were 
recently described with moderately in-
creased risks of breast cancer among Eu-
ropeans [39]. A similar eff ect is obvious 
for the spliceogenic variant that retains 
the ability to produce in-frame isoforms 
or residual full-length transcript [49– 51], 
which has been repeatedly found as Fan-
BRCA2 nonsense mutation p.Ser1882* ’in 
trans’. This patient was dia gnosed with bi-
lateral breast cancer at the ages of 36 and 
42 without symp toms of Fanconi anaemia.
Some variants were found in the nu-
clear localisation signals of BRCA1 (amino 
acids 503– 508; 606– 615)  [41]: p.Arg 
504His; p.Lys608del; or in the nuclear ex-
port sequences (amino acids 22– 39 and 
amino acids 81– 99)  [32]: p.Pro25Leu; 
p.Lys38Arg  – all of them classified as 
VUS (class 3). No variant was found 
in the nuclear localisation signals of 
BRCA2  (NLS1  spann ing amino acids 
3263– 3269; NLS2 spann ing amino acids 
3311– 3317 and putative NLS3 spann ing 
residues 3381-3385, which was found 
irrelevant)  [42]. Thus, the most car-
boxy-terminal deleterious mutation in 
BRCA2 was c.9463_9467delinsGAATGATC 
p.(Phe3155Glufs*2) remov ing both es-
sential NLSs.
Some variants were found which af-
fected the numerous phosphorylation 
sites in the BRCA1  gene: p.Ser616del, 
Ser1542Cys and in BRCA2 p.Pro3292Leu 
classifi ed as VUS (class 3). BRCA1 p.Ser-
1542Cys has been shown to eliminate 
ATM kinase binding, which is necessary 
for the phosphorylation of BRCA1  in re-
sponse to double-stranded breaks in-
duced by γ irradiation  [43]. BRCA2 
p.Pro3292Leu altered the sequence for 
CDK2  bind ing for Ser3291, and com-
pletely abolished kinase binding. It was 
shown previously that phosphorylation 
of Ser3291 by CDKs blocks the interac-
tion between BRCA2  and RAD51, serv-
ing as a molecular switch for the regu-
lation of recombination activity, which 
suggests potential signifi cance by nega-
tively aff ect ing the interaction between 
BRCA2 and RAD51 [43]. 
All VUS variants summarised in our 
study may not have been detected in 
patients analysed with Heteroduplex 
Analysis and Protein Truncation Test 
at the beginn ing and later with High 
Resolution Melt ing analysis when the 
analysis was terminated after the de-
tection of pathogenic mutation. There-
fore, the presence of some VUS in our 
analysed group may be underestimated. 
Only patients without detected patho-
genic mutations or with a double-sided 
risk were completely analysed even if 
found in the BRCT domains of the BRCA1 
gene: p.Arg1699Trp, p.Ser1715Arg, clas-
sifi ed as defi nitively pathogenic (class 5); 
p.Cys1697Arg, p.Ala1708Val classifi ed as 
likely pathogenic (class 4) on the basis 
of reported functional tests and strong 
’in silico’ predictions (Tab. 3). Two novel 
variants, p.Thr1685Asn, p.Cys1787Tyr 
were classified as likely pathogenic 
(class 4), because they are alter ing highly 
conserved residues, p.Thr1685  and 
p.Cys1787 with the same strong ’in sil-
ico’ predictions as for both previously 
reported definitively pathogenic 
variants (p.Thr1685Ile, p.Thr1685Ala 
and p.Cys1787Ser, respectively) [34,38]. 
However, the penetrance of some mis-
sense variants may be lower, as a  hy-
pomorphic eff ect was shown for BRCA1 
p.Arg1699Gln, demonstrat ing ambig-
uous functional defi ciency across mul-
tiple assays and calculated to be asso-
ciated with reduced penetrance with 
estimated cumulative risks to age 70 of 
breast or ovarian cancer of 24% [39,31].
 Besides BRCA2 c.3G>A (p.Met1?) disrupt-
ing the translation initiation codon and 
classifi ed as likely pathogenic (class 4) us-
ing a multifactorial analysis approach [40], 
several known deleterious missense mu-
tations were detected in the conserved 
DBD domain of the BRCA2 gene (Tab. 10): 
p.Trp2626Cys, p.Ile2627Phe, p.Asp2723His, 
p.Asp2723Gly, p.Arg3052Trp were clas-
sifi ed as defi nitively pathogenic (class 5; 
LOVD, Enigma Rules); p.Gly2596Glu, 
p.His2623Arg, p.Lys2630Gln, p.Ser2670 
Leu, p.Arg2784Trp, p.Glu3002Lys, p.Gly 
3076Arg, p.Asn3124Ile were classifi ed as 
likely pathogenic (class 4) on the basis 
of reported functional tests and strong 
’in silico’ predictions (Tab.  10). The novel 
BRCA2 p.Glu2663Gly was classified as 
likely pathogenic (class 4) because it alters 
a  highly conserved residue, p.Glu2663, 
with the same strong ’in silico’ predictions 
as for previously reported definitively 
pathogenic variants alter ing p.Glu2663Val 
[34]. As for BRCA1, some of the BRCA2 mis-
sense alterations might exert a hypomor-
phic eff ect. BRCA2  p.Tyr3035Ser is asso-
ciated with only a moderate risk of breast 
cancer  – (OR 2.52; P  =  0.04), similar to 
CHEK2 inactivat ing mutations [39]. In our 
family-1338 the p.Tyr3035Ser variant was 
detected in a  woman also carry ing the 
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was reclassified as VUS  [49]. Several 
BRCA2  splice variants retain the ability 
to produce partially in-frame transcripts, 
which might have a  residual function: 
c.7007G>A and c.8486A>G. 
Spliceogenic variants are more fre-
quent in BRCA2, but naturally occurr ing 
Residual full-length transcript was de-
tected in BRCA2 c.476-2A>G and c.8755-
1G>A classified as pathogenic  [52], 
whereas in c.9501+3A>T the full-length 
transcript was predominant and there-
fore the role in breast cancer risk is 
questionable and variant c.9501+3A>T 
coni anaemia-D1 associated BRCA2 mu-
tations. A possible reduced risk of spliceo-
genic and hypomorphic variants should 
be taken into consideration for clinical 
follow-up. Possible spliceogenic splice 
site alterations in the BRCA2  gene de-
tected in our study are marked in Tab. 9. 
Tab. 10. BRCA2 missense variants detected in Czech patients classifi ed as pathogenic (class 5) and likely pathogenic (class 4). 
cDNA level 
(HGVS 
nomen-
clature)
Protein
Number 
of 
families
NFE freq. 
gnom
Align-
-GVGD Prior
[reference]: 
functional defect // 
Ω mRNA analysis
[reference]: 
other 
information
LOVD-IARC class 
[4] // our class (if 
diff erent or not 
specifi ed)
c.3G>A p.Met1? 2 – 0,96 –
initiation codon // 
Ω [40]: no splice 
aberration
class 4, likely 
pathogenic
c.7787G>A p.Gly2596Glu 2 – 0,81 C65 [33]: HDR assay pathogenic
class 4, likely 
pathogenic
c.7868A>G p.His2623Arg 1 – 0,29 C25 [33]: HDR assay pathogenic
[79]: pro-
tein likelihood 
ratio: likely 
deleterious,
class 4, likely 
pathogenic
c.7878G>C p.Trp2626Cys 4 0.00090% 0,81 C65 [33]: HDR assay pathogenic
[79]: protein li-
kelihood ratio: 
likely dele-
terious; [34]: 
pathogenic; 
class 5, pathogenic
c.7879A>T p.Ile2627Phe 1 – 0,29 C15
[76]: functional assays: 
inactivated; [80]: HDR 
assay: as mutant con-
trol; [33]: HDR assay 
pathogenic
[79]: protein li-
kelihood ratio: 
likely dele-
terious; [34]: 
pathogenic; 
class 5, pathogenic
c.7888A>C p.Lys2630Gln 1 – // novel 0,66 C45 new donor site? [33]: HDR assay pathogenic
class 4, likely 
pathogenic
c.7988A>G p.Glu2663Gly 5 – // novel 0,81 C65 functionally signifi cant amino acid
[79]: protein li-
kelihood ratio: 
E2663K and 
E2663V: likely 
deleterious;[34]: 
E2663V 
- pathogenic
– // class 4, likely 
pathogenic
c.8009C>T p.Ser2670Leu 1 – 0,29 C15
[33]: HDR assay patho-
genic // Ω [50]: Partial 
Ex 18 skipping (23%) 
r.[8009c>u;7977_
8331del]; 
[79]: pro-
tein likelihood 
ratio: likely 
deleterious; 
confl icting: class 3; 
class 4, // class 4, li-
kely pathogenic
c.8167G>C p.Asp2723His 2 – 0,81 C65
[76]: functional assays: 
inactivated; [80],[33]: 
HDR assay: pathogenic
[79]: protein li-
kelihood ratio: 
likely dele-
terious; [34]: 
pathogenic; 
class 5, pathogenic
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NFE – non-Finnish European, mRNA – messen-
ger RNA, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Cancer, HDR – homology directed 
repair, mouse ES – embryonic stem cells
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tifi ed with a bi-allelic mutation in BRCA1 
c.[594-2A>C; 2681_2682delAA] with -
out symp toms of Fanconi anaemia, 
which led to the later revelation that 
c.594-2A>C was not a  high-risk mu-
native transcripts Δ(9,10), Δ11q and 
Δ(9,10,11q) are tissue-specifi c, cell-cy-
cle regulated and markedly altered in 
tumour samples  [53]. A  few years ago 
a case was described of a woman iden-
alternative splic ing at the BRCA1 might 
infl uence the signifi cance of mutations 
in particular regions as well. Accord ing 
to several reports, the relative expres-
sion levels of the most abundant alter-
Tab. 10 – continuing. BRCA2 missense variants detected in Czech patients classifi ed as pathogenic (class 5) and likely pathoge-
nic (class 4). 
cDNA level 
(HGVS 
nomen-
clature)
Protein
Number 
of 
families
NFE freq. 
gnom
Align-
-GVGD Prior
[reference]: 
functional defect // 
Ω mRNA analysis
[reference]: 
other 
information
LOVD-IARC class 
[4] // our class (if 
diff erent or not 
specifi ed)
c.8168A>G p.Asp2723Gly 3 – 0,81 C65
[76]: functional assays: 
inactivated; [80],[33]: 
HDR assay: pathoge-
nic // Predicted new 
donor site Ω [67]; [72]: 
full length transcript + 
del of 164 nt from 3´ of 
Ex 18. [50]: full length 
transcript (69,6%), Ex 
18 del-164 (25,9%); ex 
18 skipping (4,5%); 
[79]: pro-
tein likelihood 
ratio: likely 
deleterious; 
[34]: patho-
genic; [39]: 
pathogenic
class 5, pathogenic
c.8350C>T p.Arg2784Trp 1 0.00090% 0,81 C65
[81]: functional com-
plementation of 
mouse embryonic 
stem cells: poor sur-
vival, HDR capacity 
15%; [33]: HDR assay: 
pathogenic
[79]: pro-
tein likelihood 
ratio: likely 
deleterious; 
confl icting: class 3; 
class 4 // class 4, li-
kely pathogenic
c.9004G>A p.Glu3002Lys 1 – 0,66 C55
[82]: mouse ES cell-ba-
sed assay: pathogenic; 
[33]: HDR assay: patho-
genic; [81]: Functio-
nal complementation 
of mouse embryonic 
stem cells: inability to 
rescue the cell lethality
[79]: pro-
tein likelihood 
ratio: likely 
deleterious;
class 4, likely 
pathogenic
c.9154C>T p.Arg3052Trp 3 0.00090% 0,81 C65
[76]: functional as-
says: inactivated; [80]: 
HDR assay: as mutant 
control // Ω [60]: no 
aberrant 
[79]: pro-
tein likelihood 
ratio: likely 
deleterious; 
[34]: patho-
genic; [39]: 
pathogenic
class 5, pathogenic
c.9226G>A p.Gly3076Arg 1 – // novel 0,81 C65 [33]: HDR assay: pathogenic
– // class 4, likely 
pathogenic
c.9371A>T p.Asn3124Ile 16 0.0018% 0,81 C65
[82]: mouse ES cell-ba-
sed assay: pathogenic; 
[80],[33]: HDR assay: 
pathogenic
[79]: protein li-
kelihood ratio: 
likely delete-
rious; [34]: likely 
pathogenic; 
class 4, likely 
pathogenic 
cDNA – coding DNA reference sequence, HGVS – Human Genome Variation Society, NFE – non-Finnish European, mRNA – messen-
ger RNA, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on Cancer, HDR – homology directed 
repair, mouse ES – embryonic stem cells
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splice site: c.4185+1G>T, c.4185+1G>A, 
c.4185+2T>C, c.4185G>A (Tab. 2). 
The use of MLPA to detect large-scale 
rearrangements is now a standard com-
ponent of BRCA1 and BRCA2 gene test-
ing in the clinical sett ing even if it is cur-
rently also widely used CNV analysis 
with next generation sequenc ing (NGS) 
data available. Genomic rearrange-
ments accounted for 10.4% of all BRCA 
mutations detected in our study – 102 in 
BRCA1, 16 unique (Tab. 4), and only 4 in 
BRCA2, 4 unique (Tab. 11). Several break-
points in BRCA1  rearrangements were 
characterised [8] and a range of several 
deletions was confi rmed by long-range 
PCR (Tab. 4). Genomic rearrangements 
are probably frequent in the BRCA1 gene 
because of the extremely high density of 
intronic Alu repeats and the presence of 
a duplicated promoter region contain-
ing a BRCA1 pseudogene that could pro-
vide hotspots for unequal homologous 
recombination  [9]. However, genomic 
rearrangements in the BRCA2 gene are 
very rare in our region. BRCA2 deletion 
of exons 22 to 24 was detected by MLPA. 
The deletion of BRCA2 exon 18 was origi-
nally detected by CNV analysis from NGS 
data and confi rmed on two DNA sam-
ples by MLPA analysis. Suspected du-
tain signifi cance’ or even to a ’likely be-
nign variant’  [28]. BRCA1  c.4096+3A>G 
has been shown to enhance the abun-
dance of the naturally occurr ing iso-
forms: skipp ing of exon 11 and lack ing 
3309 nucleotides from exon 11 (Δ11q): 
c.[671_4096del,787_4096del] p.[Ala224_
Leu1365del,Ser264_Leu1365del], which 
was previously assumed to aff ect func-
tion  [27]. Currently, there is evidence 
that in-frame (naturally occurring) alter-
native transcripts may rescue gene func-
tionality. If the cells are viable to over-
come the loss of large segments of the 
cod ing sequences in the central part of 
the BRCA1  gene in naturally occurr ing 
isoforms Δ(9,10), Δ11q and Δ(9,10,11q), 
it is unlikely that there could be any clin-
ically signifi cant missense mutation in 
this region. A  potentially spliceogenic 
variant in the BRCA1 gene c.4675+1G>A 
was confirmed to have residual full-
length transcript [8] (Tab. 2). With the ex-
ception of one novel mutation all BRCA 
splice site mutations were character-
ised at the mRNA level (Tab. 2, 9). Novel 
BRCA1  c.4185+1G>C was classified as 
likely pathogenic (class 4) on the basis 
of the prediction to cause exon skipp-
ing and confirmed exon skipp ing for 
several other variants detected in this 
tation  [54]. The spliceogenic effect of 
c.594-2A>C was confirmed to upreg-
ulate viable Δ(9,10) in-frame isoform 
and a previously described pathogenic 
mutation specified as caus ing exon 
10 skipp ing (a truncat ing alteration) was 
reclassifi ed as a  variant of VUS  [54,55]. 
A  naturally occurr ing isoform Δ(9,10) 
might be the cause of survival in a Fan-
coni anaemia-like case with bi-allelic 
BRCA1  mutations c.594_597del (local-
ised in exon 10) and p.Arg1699Trp [56]. 
Therefore we classified our novel 
frameshift mutation located in exon 
10 of the BRCA1 gene: c.622_625dup as 
likely pathogenic (class 4), because of the 
possibility to bypass this truncat ing mu-
tation by a na turally occurr ing isoform 
Δ(9,10) and its putative hypomorphic 
eff ect. 
The comprehensive description of 
BRCA1 alternative splic ing is highly rel-
evant for dia gnosis, in particular when 
assess ing the impact of BRCA1 germline 
variants on splicing. Recently in a con-
sanguineous Danish family with several 
cases of breast/ ovarian cancer a 58-year-
-old healthy homozygous carrier of the 
BRCA1  c.4096+3A>G was identified 
which led to the reclassifi cation of this 
splice site mutation to a ’variant of uncer-
Tab. 11. BRCA2 large intragenic rearrangements detected in Czech patients. 
BRCA2 NM_000059.3) 
exons aff ected HGVS nomenclature
Number
of families Breakpoints; predicted change
LOVD-IARC class 
[4] // our class (if 
diff erent or not 
specifi ed)
deletion of exon 18 c.(7976+1_7977-1)_(8331+1_8332-1)del 1
breakpoints not characterized; detec-
ted by CNV analysis and confi rmed 
by MLPA analysis; predicted r.(7977_
8331del) => frame-shift
class 5, pathogenic
deletion of exons 19_24 c.(8331+1_8332-1)_(9256+1_9257-1)del 1
breakpoints not characterized; pre-
dicted at least: r.(8332_9256del) => 
frame-shift
class 5, pathogenic
complex rearrangement 
involving exons 21_27
c.[(8632+1_8633-
1)_(8754+1_?)dup, 
(8886_9195)del, 
(?_9256+1)_(*1_?)dup]
1
duplication of  Ex 21 and duplication 
from 3´end of Ex 24 to Ex 27 combined 
with 310bp deletion aff ecting the co-
ding sequence from exon 22 to 5´end 
of Ex 24: c.8886_9195del  (Fig. 1)
// class 4, likely 
pathogenic
duplication of exons 
22_27
c.(8754+1_8755-1)_
(*1_?)dup 1 breakpoints not characterized r?
// class 4, likely 
pathogenic
HGVS – Human Genome Variation Society, LOVD – Leiden Open Variation Database, IARC – International Agency for Research on 
Cancer, CNV – copy number variations, MLPA – Multiplex Ligation-dependent Probe Amplifi cation
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variants, even those already confi rmed as 
neutral. This can serve clinicians in our re-
gion to review data in the patient records. 
Some variants of VUS could not be clas-
sifi ed unequivocally recently. Several new 
potentially signifi cant missense variants 
have been detected for further analysis. 
The limited number of individual variants 
and lack of experimental validation lead to 
inconclusive interpretations but data shar-
ing can help to speed up clarifi cation of 
signi fi cance for some of them. Functional 
studies of potentially signifi cant variants 
and population-level data with accurate 
phenotyp ing will improve variant classifi -
cation and reduce uncertainties in future. 
By understand ing more about the VUS in-
terpretation, clinicians can help navigate 
medical decision-mak ing us ing the best 
available information and become com-
fortable with accept ing the fact that many 
DNA results cannot be interpreted with 
the tools and data avail able today.
data generated by the NGS panel are ro-
bust enough to evaluate CNVs?
Dur ing the 20  years of BRCA analysis 
a number of variants, which were origi-
nally reported as of VUS, was gradually 
reclassified as likely benign or benign 
(supplementary Tab. 6, 7, 12, 13). As soon 
as information confi rm ing the neutrality 
of any missense or intronic variant was 
available, we ceased to register their fre-
quency and stopped report ing them. Re-
ports indicate that common polymor-
phisms have not been included in the 
report and clinicians may not be aware of 
what common polymorphisms are in our 
population. Our clinicians were always in-
formed when a  variant was reclassifi ed 
as pathogenic, but they were not always 
aware of the fact of neutrality. The labora-
tory’s interpretation has always been de-
pendent on the information available at 
the time of the conclusion of the report. 
Thus, we decided to publish all detected 
plication of BRCA2  exons 22– 27  come 
originally from the Children’s Clinic after 
comparative genomic hybridisation 
analysis beyond more 3’ distant region 
and was confi rmed by MLPA. In one of 
the complex BRCA2 rearrangements we 
have not been able to reveal the exact 
character of the changes (Fig. 1). MLPA 
analysis revealed a duplication of exon 
21; deletion of exons 22 and 23 followed 
by duplication of exons 24 to exon 27. 
The deleted sequence was confi rmed by 
PCR amplifi cation and Sanger sequenc-
ing as c.8886_9195del310. The same 
MLPA profi le (and CNV profi le) was de-
tected in two individuals – in a mother 
and in her son. Probably all detected 
BRCA2 rearrangements are novel, not re-
ported in public databases from other 
populations.
We may discuss whether MLPA will re-
main the standard technology to detect 
CNVs. Has it ever evaluated whether the 
Fig. 1. Results of Multiplex Ligation-dependent Probe Amplifi cation analysis using the Coff alyser software – family-96 with complex 
BRCA2 rearrangements (identical profi le detected in mother and in her son). Duplication of  exon 21 and 3´end of exon 24 to exon 
27 combined with deletion aff ecting the coding sequence of exons 22 and 5´end of exon 24: c.8886_9195del310 – confi rmed by po-
lymerase chain reaction analysis (amplifi ed with primers for exon 21.Forward and exon 24.Reverse) and Sanger sequencing. BRCA2 
Probemix P045 (MRC Holland): probe 08267-L23772 of exon 24 (9455-9454 reverse GAAACGACAAAT-CCTATTAGGTCC ) corresponds 
to the systematic position c.9227-9228.
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